Primary and Secondary Immune Response

Q1 — Sample Band 6 response (8 marks), annotated

Under Strategy X, only staff members receive the mRNA vaccine. Each vaccinated staff member mounts a primary immune response: the mRNA instructs their cells to produce the SARS-CoV-2 spike protein antigen, triggering clonal selection of matching naive B cells, clonal expansion into plasma cells producing antibodies, and formation of memory B and T cells. The second dose triggers a secondary immune response in staff — faster, with higher antibody titres (93% achieve seroprotection at 6 months). [1 — cellular mechanism in vaccinated staff]

Residents receive no vaccine under Strategy X. They form no primary immune response, no clonal selection occurs, and no memory cells are generated. If SARS-CoV-2 later enters the facility, residents mount only a slow primary response (7–14 day lag, modest IgM antibody peak) — inadequate to prevent serious disease in frail immunocompromised individuals. This is reflected in the data: residents in Strategy X had 8.2 COVID-19 cases per 100 resident-months and 14 hospitalisations per 6-month period. [1 — no cellular immunity in residents; clinical data cited]

Strategy Y vaccinates both staff and residents. Residents mount their own primary immune response to the modified vaccine dose, with 71% achieving seroprotective antibody titres at 6 months. Although the lower antigen dose produces a weaker primary response than the full-dose schedule, 71% of residents now have memory cells and circulating antibodies. If re-exposed to the virus, their memory cells can mount a secondary response (1–3 day lag; IgG-dominated) that contains the infection more rapidly than a naive primary response would. [1 — primary response + memory formation in residents; secondary response cited]

The clinical outcome difference is substantial: Strategy Y reduced resident cases from 8.2 to 2.1 per 100 resident-months (approximately 74% fewer cases) and hospitalisations from 14 to 4 (a 71% reduction). [1 — quantitative comparison of two data measures]

Herd immunity is not achieved by Strategy X. With only 150 of 350 people immune (43%), well below any practical threshold, the pathogen can circulate freely through the unvaccinated resident population whenever an infection is imported. For immunocompromised residents who may not mount even an adequate primary response, the absence of herd immunity is especially dangerous — they cannot rely on their own immune response and depend entirely on reducing transmission among surrounding individuals. [1 — herd immunity threshold applied; immunocompromised population identified]

Strategy Y, with 81% of the combined population immune, approaches or meets herd immunity thresholds for COVID-19 variants in a closed setting, limiting transmission chains even among the 29% of residents who did not seroconvert. [1 — Strategy Y herd immunity outcome explained]

Evaluating both strategies against the biological goal of protecting the most vulnerable: Strategy Y is clearly superior — it combines individual cellular immunity in residents with population-level herd immunity that protects those who could not respond to vaccination. Strategy X fails on both counts for residents. [1 — evaluative judgement with biological reasoning]

One genuine trade-off of Strategy Y is that even a modified lower-antigen-dose vaccine may cause adverse reactions in very frail elderly residents, and 29% still fail to seroconvert — possibly because severe immunosenescence (age-related immune decline) prevents adequate clonal expansion. This means Strategy Y is not a complete solution and must be combined with infection-control measures. [1 — identified a genuine, specific limitation of preferred strategy]

Marking criteria (8 marks):

• 1 mark — Explains the cellular mechanism in vaccinated staff (primary response → clonal selection → plasma cells + memory cells via mRNA vaccine).
• 1 mark — Explains that unvaccinated residents (Strategy X) have no memory cells, will mount a slow primary response if infected, and cites data (8.2 cases / 14 hospitalisations).
• 1 mark — Explains that residents vaccinated in Strategy Y mount a primary response and form memory cells, enabling a secondary response on re-exposure, with 71% seroprotection at 6 months.
• 1 mark — Provides a quantitative comparison of at least two outcome measures (cases per 100 resident-months: 8.2 vs 2.1; hospitalisations: 14 vs 4, or equivalent).
• 1 mark — Explains why Strategy X does not achieve herd immunity (only 43% of total population immune) and identifies immunocompromised residents as the most vulnerable consequence.
• 1 mark — Explains Strategy Y's herd immunity outcome (~81% immune in combined population) and its protective effect on those who cannot mount their own response.
• 1 mark — Reaches an explicit evaluative judgement identifying Strategy Y as superior, with reasoning linked to both individual cellular immunity and population-level herd immunity.
• 1 mark — Identifies a specific, biologically grounded trade-off or limitation of Strategy Y (adverse reactions, partial seroconversion failure, or need for additional measures).

Q2 — Sample Band 6 response (7 marks), annotated

The claim contains one element that is partially correct and at least three significant scientific errors. [1 — overall evaluative stance]

Partially correct element: Residual antibodies from the first exposure (primary response) do persist in the blood for some time and can immediately bind a re-entering antigen. This provides some early-stage neutralisation and is a genuine contribution to faster re-exposure responses — so the claim is not entirely wrong on this narrow point. [1 — correctly concedes the partially valid element]

Error 1 — "Residual antibodies are the primary driver of the faster secondary response." The key mechanism is not residual antibodies but memory B and T cells. After a primary response, most plasma cells (which produce antibodies) are short-lived and die within weeks to months. Antibody titres therefore decline. What persists is a large pool of antigen-specific memory B cells in lymph nodes and bone marrow. On re-exposure, these memory B cells rapidly undergo clonal expansion into plasma cells — generating very high antibody titres within 1–3 days. If residual antibodies were the only mechanism, vaccines that produce no long-term circulating antibodies (e.g. some subunit vaccines before a booster) would provide no secondary protection — which is not observed. [1 — refutes error 1: memory B cells, clonal expansion, plasma cells all named]

Error 2 — "You don't need new cells to be activated at all." This is incorrect. The secondary response absolutely requires new cell activation — specifically, re-activation of memory B cells (and memory T cells). These memory cells are quiescent (not actively dividing) until re-exposed to the specific antigen. Upon re-exposure, they are rapidly activated, undergo clonal expansion (dividing to produce a large clone of plasma cells and additional memory cells), and then differentiate into plasma cells that secrete high-affinity IgG antibodies. Without this cellular activation and expansion, a secondary response could not produce the 10–100× higher antibody peak characteristic of the secondary response. [1 — refutes error 2: memory cell activation required; clonal expansion and plasma cell differentiation specified]

Error 3 — "Vaccination floods the body with antibodies that stay indefinitely." This is directly contradicted by the need for vaccine boosters. Antibodies are proteins that are catabolised (broken down) over weeks to months; they do not persist indefinitely. Furthermore, vaccines do not introduce pre-made antibodies — they introduce antigens (or instructions to make antigens), which the body responds to by producing its own antibodies. For tetanus, antibody titres fall below the protective threshold after approximately 10 years, which is why a decennial booster is recommended. For influenza, both the short half-life of antibodies and rapid viral mutation mean annual boosters are needed. If antibodies persisted indefinitely, no booster would ever be required. [1 — refutes error 3 with booster evidence (tetanus / influenza)]

The correct mechanism: Following vaccination (first antigen exposure), a primary immune response occurs: naive B cells undergo clonal selection (the specific B cell whose receptor matches the vaccine antigen is activated), then clonal expansion produces a large clone. Most differentiate into plasma cells that produce IgM then IgG antibodies over several weeks; a subset differentiate into memory B cells that persist long-term. On re-exposure, memory B cells — which already carry specific surface receptors for the antigen — are rapidly activated within hours, undergo clonal expansion into a new plasma cell population, and produce high-affinity IgG at 10–100× the primary titre within 1–3 days. This is the cellular basis of the faster, stronger secondary response. [1 — complete mechanistic account using memory B cell, clonal expansion, plasma cell]

In summary, the claim misattributes the speed of the secondary response solely to residual antibodies, incorrectly denies the need for new cell activation, and falsely asserts permanent antibody persistence. The actual mechanism is immunological memory stored in long-lived memory B and T cells — not in circulating antibodies. [1 — synthesising overall evaluation linking all three errors to correct mechanism]

Marking criteria (7 marks):

• 1 mark — States an overall evaluative stance (e.g. "one element is partially correct; three errors are present").
• 1 mark — Correctly identifies and explains the partially valid element (residual antibodies do contribute some early neutralisation).
• 1 mark — Refutes Error 1 (residual antibodies as primary driver): identifies memory B cells, clonal expansion, and plasma cell production as the actual mechanism; uses all three terms correctly.
• 1 mark — Refutes Error 2 (no new cells needed): explains that memory B cells must be re-activated and undergo clonal expansion — no cell activation = no 10–100× antibody surge.
• 1 mark — Refutes Error 3 (antibodies stay indefinitely): uses booster evidence (tetanus every 10 years; influenza annually) to show antibody titres fall below protective threshold over time.
• 1 mark — Provides a complete mechanistic account of the secondary response using all three required terms (memory B cell, clonal expansion, plasma cell).
• 1 mark — Synthesises a clear overall conclusion that links all errors to the correct mechanism, using precise lesson terminology.